Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis
Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 2
Abstract
Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demonstrated that the addition of taxanes to anthracycline-based chemotherapy improves the outcome in either concurrent or sequential schedule. Nowadays, the TAC regimen (docetaxel, doxorubicin and cyclophosphamide) is a standard treatment in both node-positive and high-risk node-negative early breast cancer. Doxorubicin and epirubicin are equivalent, but at similar doses epirubicin appears to have a better side effects profile than doxorubicin in terms of myelosuppression and cardiotoxicity. We conducted a retrospective study to establish the role of TEC (epirubicin) regimen in adjuvant setting. Methods: Pre- or post-menopausal women, with stage I-III breast cancer, PS ECOG 0-2 and normal left ventricular ejection fraction, were eligible. TEC chemotherapy at median doses of docetaxel 75 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 was administered IV on day 1 every three weeks for 6 cycles. The primary endpoint was toxicity; secondary endpoints were DFS and OS. Results: Thirty-three consecutive female patients were retrospectively enrolled. The median age was 57 years old. Eighty eight percentage of patients completed the treatment plan. In 21.2% of cases a dose reduction was performed and these patients needed a chemotherapy interval prolongation. The main side effects were neutropenia G3-4 (21.2%; 95% CI, 9.8-37.5), allergic reaction G3 to docetaxel (6.1%; 95% CI, 1.0-18.6) and febrile neutropenia (3.0%; 95% CI, 0.1-14.0), while cardiotoxicity was absent (95% CI, 0-8.7%). Globally, the percentage of any other severe side effect was very low and no one toxic death was seen. The 3-year DFS and OS were 89.9% (95% CI, 79.0-100) and 93.8% (95% CI, 85.6-100), respectively. Conclusions: As compared to TAC treatment, TEC regimen with epirubicin 60 mg/m2 is feasible and well tolerated adjuvant chemotherapy in breast cancer, with acceptable and manageable toxicity.
Authors and Affiliations
Galdy S, Zenoni D, Galmozzi A, Mauri CM, Cazzaniga S
Keywords
Related Articles
- EP ID EP547320
- DOI 10.14312/2052-4994.2014-6
- Views 78
- Downloads 0
Therapy-related acute myeloid leukemia with chromosomal abnormalities involving t(9;22)(q34;q11) and t(3;21)(q26;q22) during chemotherapy for follicular lymphoma
This report describes a case of a patient who developed therapy-related acute myeloid leukemia five years after initiating chemotherapy for follicular lymphoma. The patient had been treated with multiple chemotherapeutic...
Burden, quality of life and distress of the main caregiver in head and neck, cervix and rectal cancer patients
Purpose: Based on Portuguese experience, current practice does not focus sufficiently on the caregiver needs through caring of the cancer patient. Understanding the impact of different tumor types on caregiver burden, qu...
Usefulness of the Glasgow prognostic score for predicting survival in patients with resected non-small cell lung cancer
Background: Few studies have investigated whether the Glasgow prognostic score (GPS), an inflammation based prognostic score, is useful for postoperative prognosis of non-small cell lung cancer (NSCLC). Materials and met...
Prognostic serum biomarkers for colorectal cancer – Review
Background: Colorectal cancer (CRC) is one of the most common malignancies in developed countries. Research for diagnostic and prognostic biomarkers is increasing. There are more than 750,000 papers indexed in PubMed dir...
Primary malignant giant cell tumour of the proximal tibia: a case report
Primary malignant giant cell tumour of bone is extremely rare and very few examples exist in the literature. We report a case of a 37-year-old man with a primary malignant giant cell tumour of the proximal tibia. He was...